US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
San Diego-based Axiom Biosciences said it intends to become the first US biotech to list on the Hong Kong Stock Exchange, seeking $150-200 million next year to fund its regenerative medicine pipeline. The company, formerly Cytonus Therapeutics, cites Asian partners and may pursue a later US secondary listing.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Bloomberg_crypto.
Entities in this story
Want the full article?
Continue reading on Bloomberg_crypto →